BioSight
Companies
JOHNSON & JOHNSON logo

JNJ

NYSENEW BRUNSWICK, NJ
JOHNSON & JOHNSON

Johnson & Johnson operates as a holding company with approximately 138,200 employees developing, manufacturing, and selling healthcare products globally across two segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on prescription drugs across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular/metabolic conditions, with marketed products including CAR-T cell therapies, monoclonal antibodies, bispecific antibodies, and small-molecule inhibitors at various clinical stages. Products are distributed through retailers, wholesalers, hospitals, and healthcare professionals.

$229.85+51.12%1Y
JNJ · daily close · illustrative · 0 catalysts marked
$132$164$195$227$259Apr '25Aug '25Dec '25Apr '26
1Y high$248.561Y low$142.42range$106.14(75%)past catalysts

Pipeline5

Cetuximab
Phase 3Carcinoma, Squamous Cell
small-molecule
JNJ-90301900 (NBTXR3)
Phase 3Carcinoma, Squamous Cell
small-molecule
Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
Phase 2Non-Small Cell Lung Cancer
small-molecule
Durvalumab
Phase 2Non-Small Cell Lung Cancer
small-molecule
JNJ-90301900
Phase 2Non-Small Cell Lung Cancer
small-molecule

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar